Octreotide

Synthetic Somatostatin AnalogRx: PrescriptionCompound: Approved

Also known as: Longastatina, Octreotide, Octreotide acetate, Sandostatin, Sandostatin LAR, SMS 201-995

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Source Octreotide at Peptiology

Save 10% with code PEPTI-BOSSRABBIT-10

Shop Now & Save 10% →

Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.

Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.

Summary

Octreotide is a synthetic analogue of the hormone somatostatin that binds somatostatin receptors to suppress hormone secretion and reduce splanchnic blood flow. It is used clinically to manage symptoms of neuroendocrine tumours, control acute variceal bleeding, and treat other hormone‑related conditions.

Mechanism of Action

Binds to somatostatin receptors (primarily SSTR2 and SSTR5), inhibiting the release of growth hormone, insulin, glucagon, gastrin, and other gastrointestinal hormones; also reduces splanchnic blood flow and portal pressure.

What the Research Shows

Randomised phase 3 trials (NETTER‑2, NETTER‑1) compared 177Lu‑Dotatate plus long‑acting octreotide with high‑dose octreotide alone in patients with advanced gastroenteropancreatic or mid‑gut neuroendocrine tumours. NETTER‑2 showed a marked extension of median progression‑free survival (22.8 vs 8.5 months) with similar overall adverse‑event rates. NETTER‑1 confirmed progression‑free survival benefit but did not achieve a statistically significant overall‑survival advantage (48.0 vs 36.3 months). A systematic review of 21 RCTs in acute variceal bleeding found octreotide (or somatostatin) provided comparable mortality to terlipressin/vasopressin but with fewer adverse events. No other trials were identified in the supplied abstracts.

Reported Benefits

Clinical trials demonstrate that octreotide, when combined with peptide receptor radionuclide therapy, significantly prolongs progression‑free survival in advanced neuroendocrine tumours. In acute variceal bleeding, octreotide offers similar bleeding control to vasopressin‑based regimens while reducing the risk of drug‑related adverse events, supporting its use as a safer vasoactive option.

Limitations of the Evidence

Overall survival benefit of octreotide‑based regimens remains unproven in neuroendocrine tumour trials. Evidence is confined to somatostatin‑receptor positive, well‑differentiated tumours and may not extrapolate to other cancers or to pediatric populations. Data on long‑term safety, especially rare haematologic toxicities, are limited, and comparative effectiveness in bleeding is based on heterogeneous studies.

Safety Considerations

Adverse events were reported in over 90% of patients receiving octreotide in NETTER trials, though most were low grade; serious events were rare. Myelodysplastic syndrome occurred in ~2% of patients receiving 177Lu‑Dotatate plus octreotide. In variceal bleeding studies, octreotide showed fewer drug‑related adverse events than vasopressin/terlipressin. No treatment‑related deaths were recorded in the NETTER studies.

How It Is Administered

Octreotide is administered by intramuscular, subcutaneous, or intravenous injection. The long‑acting repeatable (LAR) formulation is given intramuscularly every 4 weeks (30 mg) for chronic indications; short‑acting formulations are given subcutaneously or intravenously for acute control. Dosing schedules vary by indication and clinical protocol.

Routes of Administration

IntramuscularIntravenousSubcutaneous

Goals & Uses

  • Esophageal variceal bleedingGastroenterologyHigh
  • Acromegaly managementEndocrinologyHigh
  • Neuroendocrine tumor (NET) antiproliferative therapyOncologyHigh
  • Prevent bleeding from esophageal varicesGastroenterologyModerate
  • Carcinoid syndrome symptom controlOncology/GastroenterologyHigh
  • Mitigate carcinoid syndrome symptomsOncologyHigh
  • Treat vasoactive intestinal peptide tumors (VIPoma)GastroenterologyModerate
  • Control acromegalyEndocrineHigh
  • Dumping syndrome managementGastroenterologyModerate
  • VIPoma managementOncology / NeuroendocrineHigh

Contraindications

  • PregnancyPopulationModeratePotential fetal risk or insufficient safety data
  • Hypersensitivity to octreotide or any excipientsAllergyHigh
  • Severe biliary obstruction or active gallbladder diseaseGastrointestinalModerate
  • Hypersensitivity to octreotide or excipientsAllergyHigh
  • Pregnancy (relative)ReproductiveModerate

Adverse Effects

  • Gastrointestinal disturbances (nausea, diarrhea, abdominal pain)GastrointestinalCommon
  • Cholelithiasis / gallstonesGastrointestinalCommon
  • Hyperglycemia or hypoglycemiaMetabolic/EndocrineCommon
  • Injection site reactionsLocalCommon
  • Bradycardia / cardiac conduction abnormalitiesCardiovascularUncommon
  • Nausea and abdominal painGastrointestinalCommon
  • Gallstone formationHepatobiliaryCommon
  • Hypoglycemia or hyperglycemiaMetabolicUncommon
  • HypothyroidismEndocrineUncommon

Drug Interactions

  • QT-prolonging drugs (e.g., amiodarone, sotalol)Moderate
  • Insulin / Oral antidiabeticsModerate
  • Beta-blockersModerate
  • CyclosporineModerate
  • BromocriptineLow
  • Insulin or oral hypoglycemicsModerate
  • Other somatostatin analogsLow

Population Constraints

  • PregnancyReproductive SafetyRelative
  • Hepatic impairment (cirrhosis)Organ ImpairmentRelative
  • Renal impairmentOrgan ImpairmentRelative
  • Pediatric patientsAgeRelative
  • ElderlyAgeRelative
  • Pregnant womenReproductiveRelative
  • Diabetic PatientsMetabolicRelative
  • BreastfeedingReproductiveRelative

Regulatory Status

  • European UnionApprovedApproved: Acromegaly, Carcinoid syndrome, VIPoma, Bleeding esophageal varices
  • United StatesApprovedApproved: Acromegaly, Carcinoid syndrome diarrhea, VIPomaShort‑acting and long‑acting depot formulations available
  • United KingdomApprovedApproved: Acromegaly, Carcinoid syndrome, VIPoma

FDA‑approved (1988) for acromegaly and carcinoid syndrome; also approved in EU and UK for similar indications. Long‑acting depot formulation (Octreotide LAR) approved for chronic use.

Evidence & Sources

Frequently Asked Questions

What types of tumours are treated with octreotide?

Octreotide is used primarily for somatostatin‑receptor positive, well‑differentiated gastroenteropancreatic and mid‑gut neuroendocrine tumours, especially when combined with peptide receptor radionuclide therapy to extend progression‑free survival.

Is octreotide effective for stopping bleeding from oesophageal varices?

Evidence from a systematic review of randomised trials indicates octreotide (or somatostatin) achieves similar control of acute variceal bleeding as vasopressin‑based agents, but with a lower incidence of drug‑related adverse events.

What are the common side effects of octreotide?

Patients frequently experience mild adverse events such as gastrointestinal discomfort, gallstone formation, and injection‑site reactions. Serious toxicities are uncommon, though rare cases of myelodysplastic syndrome have been reported when octreotide is used with radiolabelled therapy.

How is the long‑acting octreotide formulation administered?

The long‑acting repeatable (LAR) form is given as a deep intramuscular injection, typically 30 mg every four weeks, allowing sustained drug levels for chronic disease management.

Does octreotide improve overall survival in neuroendocrine tumour patients?

Current phase 3 data show a clear progression‑free survival benefit, but the improvement in overall survival did not reach statistical significance in the NETTER‑1 trial, indicating uncertain impact on long‑term mortality.

What is Octreotide?

Octreotide is a synthetic analogue of the hormone somatostatin that binds somatostatin receptors to suppress hormone secretion and reduce splanchnic blood flow. It is used clinically to manage symptoms of neuroendocrine tumours, control acute variceal bleeding, and treat other hormone‑related conditions.

What is Octreotide used for?

Octreotide is educationally associated with: Esophageal variceal bleeding, Acromegaly management, Neuroendocrine tumor (NET) antiproliferative therapy, Prevent bleeding from esophageal varices, Carcinoid syndrome symptom control, Mitigate carcinoid syndrome symptoms, Treat vasoactive intestinal peptide tumors (VIPoma), Control acromegaly, Dumping syndrome management, VIPoma management. Educational only — not medical advice.

How is Octreotide administered?

Recorded routes of administration: Intramuscular, Intravenous, Subcutaneous.

What are the potential side effects of Octreotide?

Reported adverse effects include: Gastrointestinal disturbances (nausea, diarrhea, abdominal pain), Cholelithiasis / gallstones, Hyperglycemia or hypoglycemia, Injection site reactions, Bradycardia / cardiac conduction abnormalities, Nausea and abdominal pain, Gallstone formation, Hypoglycemia or hyperglycemia, Hypothyroidism. This list is not exhaustive — consult a qualified clinician.

Who should avoid Octreotide?

Recorded contraindications: Pregnancy, Hypersensitivity to octreotide or any excipients, Severe biliary obstruction or active gallbladder disease, Hypersensitivity to octreotide or excipients, Pregnancy (relative). Consult a qualified clinician before use.

More Somatostatin Analogues

See all Somatostatin Analogues →

Browse All PeptidesBuild My Stack